VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes
Vaccine Information
  • Vaccine Name: S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes
  • Target Pathogen: Shigella
  • Target Disease: Shigellosis
  • Vaccine Ontology ID: VO_0000682
  • Type: Subunit vaccine
  • Antigen: The antigen for this acellular vaccine is purified Shigella flexneri LPS (Orr et al., 1993).
  • Preparation: Purified shigella LPS and group C serotype 2b N. meningitidis outer membrane proteins were mixed at a 1:1 ratio in PBS containing 1% Empigen. The mixture was dialyzed across a dialysis membrane against PBS. Samples of the purified LPS were mixed with PBS and sodium bicarbonate (Orr et al., 1993).
  • Virulence: Strong anamnestic responses were found , so acellular Shigella vaccines can protect against Shigella infection (Orr et al., 1993).
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: BALB/c mice were were immunized either orally or intranasally with 100 miroliters of PBS containing 100 micrograms of LPS with 0.2 M sodium bicarbonate that was given either alone or complexed with 100 micrograms of proteosomesusing a bent metal tube. For intranasal immunization, 25 micrograms of LPS either alone or complexed with 10 micrograms of proteosomeswas slowly placed into one or both of the nares. The control group recieved diluent without antigen (Orr et al., 1993).
  • Immune Response: Vaccination produced high levels of anti-LPS IgG and anti-LPS IgA in mice immunized two or three times (Orr et al., 1993).
  • Challenge Protocol: Mice were challenged with LPS two weeks after their last immunization (Orr et al., 1993).
  • Efficacy: All mice in control groups were infected. 14 out of 19 and 11 out of 16 mice were protected from severe infection after intranasal or oral vaccination. 9 out of 16 animals were protected from any illness (Orr et al., 1993).

Guinea pig Response

  • Host Strain: DH
  • Vaccination Protocol: Anesthetized guinea pigs were immunized. Orally, they each received 200 microliters of PBS with sodium bicarbonate and 200 micrograms of the LPS complex. Intranasally, each guinea pig received 50 microliters of PBS with 40 micrograms of the LPS complex (Orr et al., 1993).
  • Immune Response: Guinea pig titers proved strong anti-LPS IgG antibodies and anti-LPS IgA antibodies (Orr et al., 1993).
  • Challenge Protocol: The conjunctival sac of one eye of each animal was inoculated with 30 microliters of a suspension containing and estimeted 108 of homologous bacteria (Orr et al., 1993).
  • Efficacy: The vaccines elicited an in vivo protection against homologous bacteria (Orr et al., 1993).
References
Orr et al., 1993: Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infection and immunity. 1993; 61(6); 2390-2395. [PubMed: 8500877].